Beth Israel Deaconess Medical Center (BIDMC) and their Cancer Center are actively participating to support patients during National Prostate Month. Their Prostate Cancer Program has several expert sources to drive progress in the fight against prostate cancer. Interesting updates include the Prostate Cancer Active Surveillance Study (nation’s largest clinical trial for active surveillance), a BIDMC-developed tool to assess and strengthen quality of life and treatment options, such as a non-invasive alternatives to surgery and clinical trials.
It is known that 1 in 9 men will be diagnosed with prostate cancer during their lifetime, reports the American Cancer Society. BIDMC is dedicated to supporting patients as they navigate their diagnosis and treatment options through a holistic approach. Some recent updates from BIDMC:
- Active Surveillance – The Prostate Cancer Active Surveillance Study, (PASS), the nation’s largest clinical trial of active surveillance, is designed to identify and validate biomarkers—proteins, DNA, RNA and hormones—that predict aggressive prostate cancer. BIDMC is the only academic medical center in the Northeast participating in this study, under the leadership of Principal Investigators and urologic surgeons Dr. Andrew Wagner and Dr. Peter Chang.
- The Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) is a convenient tool for health care providers to measure urinary, bowel, sexual, and vitality/hormonal health. This quality of life instrument, developed by clinician researchers at Beth Israel Deaconess Medical Center, including Dr. Peter Chang, was designed specifically for use in the routine clinical care of prostate cancer patients.
- CyberKnife – CyberKnife is a non-invasive alternative to surgery that can treat both cancerous and non-cancerous tumors anywhere in the body, including the prostate. BIDMC experts have utilized the tool for many years, including radiation oncologist Dr. Irving Kaplan.
- The latest treatment options, including clinical trials– Medical oncologists Dr. Glenn Bubley, Dr. David Einstein and Dr. Rupal Bhatt can speak to current prostate cancer therapies in the clinic as well as those currently being studied in clinical trials.
Beth Israel Deaconess Medical Center (BIDMC)
Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts is a teaching hospital of Harvard Medical School. It was formed out of the 1996 merger of Beth Israel Hospital (founded in 1916) and New England Deaconess Hospital (founded in 1896). Among independent teaching hospitals, Beth Israel Deaconess Medical Center consistently ranks in the top three recipients of biomedical research funding from the National Institutes of Health. Research funding totals nearly $200 million annually. BIDMC researchers run more than 850 active sponsored projects and 200 clinical trials. The Harvard-Thorndike General Clinical Research Center, the oldest clinical research laboratory in the United States, has been located on this site since 1973.
BIDMC is involved with a wide array of clinical research programs. Their Clinical Trials Office (CTO) offers a central and comprehensive program of financial, legal, and administrative support to the research community at BIDMC—all for the pursuit of improved health care for the community, education, and advancement of knowledge.